

Estimating the burden and cost of infectious intestinal disease in the Maltese community

C. GAUCI¹*, H. GILLES², S. O'BRIEN³, J. MAMO⁴, I. STABILE⁴, F. M. RUGGERI⁵,
N. CALLEJA⁶ AND G. SPITERI¹

¹ *Disease Surveillance Unit, Department of Public Health, Msida, Malta*

² *University of Liverpool, Liverpool, UK*

³ *University of Manchester, Hope Clinical Academic Group, Hope Hospital, Salford, UK*

⁴ *University of Malta, Medical School, St Luke's Hospital, G'Mangia, Malta*

⁵ *Istituto Superiore di Sanita, Department of Food Safety and Animal Health, Rome, Italy*

⁶ *Medical Statistics, Department of Health Information, G'Mangia Hill, G'Mangia, Malta*

(Accepted 11 January 2007; first published online 21 February 2007)

SUMMARY

The aim of this study was to estimate the burden of infectious intestinal disease (IID) and cost of illness at the community level from a societal aspect. A retrospective, age-stratified cross-sectional telephone study was carried out in Malta in 2004–2005. The number of cases, resources used and cost of resources were computed. The resources involved direct costs (health-care services, stool culture tests, medicines and personal costs) and indirect costs (costs from lost employment by cases and caregivers). This study estimated 0·421 (95% CI 0·092–0·771) separate episodes of IID per person per year in Malta which corresponds to 164 471 (95% CI 35 941–301 205) episodes of IID per year or 450 (95% CI 98–825) episodes of IID each day. The largest proportion of cost is due to provision of health-care services with €10 454 901 [Maltese liri (Lm) 4 558 970] per year; followed by €963 295 (Lm 2 209 393) in lost productivity; €1 286 286 (Lm 561 078) in medicines; €152 335 (Lm 66 452) in stool culture testing and €71 487 (Lm 31 183) in personal costs, giving a total cost of illness of over €16 million (7 million Lm) per year. The burden and cost of IID are high enough to justify efforts to control the illness. Such estimates are important to assess the cost-effectiveness of proposed specific interventions.

INTRODUCTION

Infectious intestinal disease (IID) is an important cause of morbidity and mortality throughout the world. The burden of illness is highest in developing countries with an estimated 6800 children dying on average each day from diarrhoeal diseases worldwide [1–3]. Deaths from IID in developed countries are less common, but still significant with an estimated 6400

deaths per year in the United States [4] and a significant morbidity. IID is usually self-limiting and does not generally lead to high costs to the particular individual. However, due to the large number of persons affected, the total costs at societal level can be considerable [5–7]. A number of international studies have been performed to estimate the health burden and cost of illness using different approaches [5, 7–16]. In Malta, no estimates have been performed on the costs of IID at community level. In 2003, the Department of Health (Malta) embarked on a series of studies on the surveillance of IID. One component was a community-based population study. One of

* Author for correspondence: Dr C. Gauci, Head of Disease Surveillance Unit, Disease Surveillance Unit, Public Health Department, 37–39 Rue D'Argens, Msida, Malta.
(Email: charmaine.gauci@gov.mt)

the objectives of this study was to estimate the burden of IID in terms of magnitude and cost of illness at the community level from a societal aspect. Such estimates are important to be able to compare with costs of possible different public health interventions and to assess the potential cost-effectiveness of specific interventions which would guide policy-making.

MATERIALS AND METHODS

To determine the burden and cost-of-illness due to IID, the number of cases, the number of resource units used and the cost per resource unit were obtained from the community population study. This was a retrospective cross-sectional study of a random sample of persons from among the Maltese population. A telephone interview was conducted between April 2004 and December 2005 and collected information on self-reported symptoms of IID at community level. Individuals who reported at least three episodes of diarrhoea (defined as loose stool) within 24 h or vomiting at least three times in 24 h, or suffered diarrhoea or vomiting with two or more additional symptoms in 24 h over the previous 28 days were defined as cases. Details on methodology are described in detail elsewhere [17–19].

Estimated number of cases

The period prevalence was obtained by dividing the number of cases by the total number of respondents. This was weighted to the age and gender structure of the Maltese population, and was applied to the population to obtain the expected number of cases per day and year in Malta. The number of IID episodes per person per year was obtained using the Poisson distribution to account for those cases that had more than one episode during the previous 28 days [18].

Estimated resources used

Cases were asked questions regarding health-care use, use of medications, stool culture tests, personal costs, and loss of school or productivity. Since the use of resources generally depends on the illness severity [16], the self-perceived severity of illness, was thus categorized:

Mild cases. Cases with symptoms who felt slightly unwell but able to do all normal activities.

Moderate cases. Cases with symptoms who felt quite unwell but were still able to do most activities as well as those having to stay at home but who were able to get out of bed for limited activities.

Severe cases. Cases who had suffered the symptoms, who were confined to their home and being unable to do any of the usual activities as well as those who required hospitalization as a result of the illness.

Estimated costs of resources

The costs of resources comprised both direct and indirect costs. Costs were in Maltese lira (Lm) which is equivalent to €2.29. Direct costs included health-care provider (HCP) visits, hospitalization, stool culture testing, medications used directly for their illness and direct personal costs. Cases were asked for specific costs including telephone calls, special foods and drink, leisure items, new clothing, new bedding and cleaning materials. Indirect costs included missed work by the case or by other persons who cared for the case.

The average cost of health-care services and hospitalization costs were obtained from the fees legislation which was issued in 2004 [20]. The prices of medicines were obtained from the average selling prices obtained from a convenience sample of ten local pharmacies (of 207). The cost of analysis of a stool sample was estimated from the average total cost that private laboratories charge for testing in such cases, that is for bacteria (*Salmonella*, *Campylobacter*, *E. coli*, *Shigella*), rotavirus and protozoa.

To calculate accurately the indirect cost of IID due to lost productivity, the occupation of the case and of the person who missed work to care for a case was required. Since this information was not available for all the cases, the education level was used to calculate the salary under the assumption that cases work within their educational level. The education level was regrouped into six categories and the equivalent salary was obtained from information collected from the 2002 Health Interview Survey [21]. It was assumed there are 261 working days per year in calculating the salary per work day lost (public holidays were not taken in account since these vary from year to year). The mean days off work was calculated for all persons who were in employment at the time. For school days lost this was calculated for those who were attending school at the time of the interview.

The total costs were calculated from the above and reported per case of IID, overall per day and overall per year. Costing for IID was also calculated according to the grading of severity. Testing between two proportions was carried out using χ^2 or Fisher's exact tests. Kaplan–Meier life tables were used for the calculation of the duration of illness since some of the cases were still symptomatic at the time of illness hence the exact duration of illness could not be calculated for all cases.

RESULTS

Rate of IID

The average monthly prevalence of 3.18% (95% CI 0.7–5.74) is the proportion of persons in the population who, at any point in time in the year, could report having had at least one episode of IID in the previous 28 days. Using Poisson distribution, a mean rate of 0.421 (95% CI 0.092–0.771) separate episodes of IID per person per year was estimated. When this figure is extrapolated to the general population, it corresponds to 164 471 (95% CI 35 941–301 205) episodes of IID per year in the Maltese Islands or an equivalent of 450 (95% CI 98–825) episodes of IID each day.

Severity of illness

Of the cases ($n=99$), 15% reported feeling a little out of the ordinary, 23% reported feeling slightly unwell but were able to do most activities (moderate IID), 20% reported feeling quite unwell but able to do all activities, 20% reported having to stay at home but were able to get out of bed for limited activities, 15% were confined at home and unable to do any usual activities whilst 4.8% required hospitalization.

The mean duration for which cases were unable to perform usual activities due to IID was 2.19 days (95% CI 1.94–2.45) with a mode of 2 days. The mean duration of time unable to engage in leisure activities was 2.36 days (95% CI 2.43–2.65) with a mode of 2 days.

The severity of illness was mild in 54.5% ($n=54$) of cases, moderate in 22.2% ($n=22$) of cases and severe in 23.3% ($n=23$) of cases. The majority of severe cases occurred in the 2–4 years age group whilst the mildest cases occurred in the 31–44 years age group (Fig. 1). Mild and severe cases were commoner among




Fig. 1. Category of severity of infectious intestinal disease (IID) illness per age group ($n=99$). ■, Mild; □, moderate; ▒, severe.

females whilst moderate severity illness was commoner in males.

Days taken off work and school

Of all the persons affected, 14% ($n=14$) missed paid employment due to the illness. The number of days off work ranged from 0 to 7 days. For those who had to take time off, the mean time was 1.86 days (95% CI 1.79–1.92) while the median and mode was 2 days. A number of cases did not require any time off work. This represents an average of 0.26 days of work lost per person suffering from IID.

The number of days lost varied with the severity of illness with 11.7% ($n=11$) of severe cases requiring an average of 5 days off work and none for mild cases.

For 4.4% ($n=4$) of cases, other persons took time off work to care for the case. The number of days required ranged from 1 to 5 days with a mean duration of 0.11 days (95% CI 0.22–0.002), which is equivalent to 0.0048 days of work lost per person suffering from IID. The days required off work varied with the severity of illness of the case. The median days off work was 3 days for both mild cases and severe cases and 1 day for moderate cases. The total number of days lost off work by the case was 0.26 and by the caregiver was 0.0048 which was equivalent to 0.2648 days lost per person with IID. When extrapolated to the population this is equivalent to 43 552 days lost each year in Malta due to IID. The lost

Table 1. *Costs in Maltese liri (Lm) of consultation for IID with a health-care professional*

Health-care provider visited	Average cost per visit (Lm)	Cost per IID case (Lm)	Total cost for cases per day (Lm) ($\times 450$)	Total cost for cases per year (Lm) ($\times 164\,471$)
Accident & Emergency department	20	1.82	818	299 038
Doctor's surgery	3	0.85	381	139 551
Health centre	10	0.20	90	33 226
Hospital admission	110 per day	26.67	11 999	4 385 893
Total		29.54	13 290	4 558 970

productivity for the case was Lm 5.41 per day, and the lost productivity for the caregivers was Lm 8.02 per day for a total of Lm 13.43 per day per case of IID. This translates into a total of Lm 6044 of lost productivity due to IID per day in Malta or Lm 2 209 390 per year.

For 16% ($n=16$) of cases, school was missed because of the illness. The number of days missed ranged in duration from 0 to 6 days with a mean of 0.49 days (95% CI 0.37–1.45). This is equivalent to 0.0784 days of school lost per person with IID. The days missed varied according to the severity of illness with 12.5% of mild cases, 45.8% of moderate cases and 29.2% of severe cases of cases aged 3–16 years missing school.

Another 4.6% persons missed school because of another person with IID, for example siblings. The duration ranged from 1 to 5 days with a mean duration of 3.04 days (95% CI 1.39–4.64) and median and mode of 2 days. This is equivalent to 0.1398 days of school lost per person with IID, giving a total of 0.218 days of school lost per person with IID.

Health-care seeking behaviour

Of the cases, 55.5% (95% CI 46.68–64.32, $n=55$) sought the advice of a HCP by phone or by visiting general practitioner (GP). Of those who did not seek help, the majority (48%), did not do so because they felt it would be inadequate and that it would not make a difference to the outcome of their illness. The duration of illness influenced the health-seeking behaviour. The mean duration of illness in cases that sought help from a HCP was 7.61 days (95% CI 3.91–11.32) whilst in those who did not, it was less, 4.82 days (95% CI 2.99–6.65). The majority of those who contacted a HCP, consulted a doctor (95.6%, $n=53$) while 4.6% ($n=2$) consulted a pharmacist.

Almost half of the cases (48.4%, 95% CI 39.58–57.22, $n=26$) visited a HCP for their illness. Of these, 38.6% visited a GP, 14.2% visited the casualty department, 1.3% visited a health centre (public GP) and 3.5% visited another HCP.

A total of 89 visits to health professionals were recorded with a mean of 0.73 visits per case (95% CI 0.51–0.95). Of those attending the HCP, 61% were accompanied by someone, who in 4.4% of cases, had to make arrangements to accompany that person. For 23.9% of cases, a HCP visited the case at home. The commonest factor influencing the decision of the patient to visit the HCP was because they were suffering from diarrhoea. Age was significantly associated with health-care-seeking behaviour ($P=0.011$). Parents of children aged 0–4 years and those aged 12–18 years were found to consult more frequently than other age groups.

Of the cases identified, 6.35% (95% CI –2.10 to 14.80, $n=3$) required admission to hospital. The number of days of hospitalization ranged from 1 day to 35 days with a mean duration of 6.6 days (95% CI –0.69 to 13.89). Of cases who were admitted, 74.7% required a person to accompany the case, usually the mother for children. The maximum duration another person stayed with the case in hospital was of 5 days.

No complications were reported from any of the cases at the time of interview. However, no long-term follow up was performed. The costs incurred from health-care visits are listed in Table 1.

Stool sample requests and submission

Of the cases who visited a HCP for IID, 11.2% (95% CI 1.79–20.61, $n=6$) were asked to submit a stool sample for analysis. This represents 5.4% of all the estimated cases suffering from IID. Of those who were




Fig. 2. Estimated number of persons with infectious intestinal disease (IID) in the community, consulting a health-care provider (HCP) and submitting stools for analysis.

asked for a sample, 14.5% were asked by the ward doctor or nurse, 73.9% by the hospital emergency doctor or nurse and 11.7% by a GP. The accuracy of these estimates is limited since they are based on a small number of patients since numerically of 99 cases, only two actually submitted a stool sample. In practice it has been shown that very few doctors actually ask patients to submit stools for analysis. The total costs incurred in sampling and analysis was Lm 40.

From the analysis of health-care-seeking behaviour and stool sample submission, the values can be extrapolated in that for every stool specimen submitted, there are 27 persons consulting a HCP and 50 persons suffering from IID in the community (Fig. 2).

Extrapolating these estimates to the general population, it was calculated that there are 450 new episodes of IID each day in the community, of which 247 would consult a HCP and nine would submit stools for analysis (Fig. 3).

Medication

Of the cases with IID, 60.2% (51.58–68.82, $n=60$) reported taking some form of medication as a form of treatment for IID. The commonest medicinal taken was oral rehydration therapy (34.2%, 95% CI 25.77–42.63) which is usually purchased as an over-the-counter medicine from pharmacies. Alternative medications or remedies taken include chamomile tea,




Fig. 3. Extrapolated number of persons with infectious intestinal disease (IID) in Malta each day, showing the number who visit a health care provider (HCP) and submit a stool sample.

green tea, herbal tea, orange blossom water or tea with lemon. A higher proportion of females (63.9%) reported taking medicines than males in all age groups.

Using Kaplan–Meier life tables, cases who took medication were ill for an average of 7.03 days (95% CI 3.87–10.19) whilst those who did not take medications were ill for an average of 4.98 days (95% CI 2.73–7.22).

When testing by univariate and multivariate analysis for statistical significance, age, gender and duration of illness were not found to be significantly associated with medicinal use, both independently and when adjusted. The costs incurred in the required use of medicines are listed in Table 2.

Other costs

Costs of different items including special foods and drink, leisure items, new clothing, new bedding, prepaid school, prepaid leisure activities, other costs and costs related to phone calls amounted to Lm 0.189 per case which is equivalent to Lm 85.32 per day or Lm 31 183 overall in the community per year.

Total costs of IID

Direct costs included health-care professional visits and house calls, use of medicinals, costs of laboratory

Table 2. *Costs in Maltese liri (Lm) incurred from use of medicines*

Medication	Cost per IID case (Lm)	Total cost for cases per day (Lm) ($\times 450$)	Total cost for cases per year (Lm) ($\times 164\,471$)
Analgesic	0.255	114.55	41 865
Anti-diarrhoeals	0.645	290.18	106 058
Antihistamines	0.032	14.41	5266
Anti-nauseants	0.429	193.09	70 573
Oral rehydration	1.324	595.64	217 699
Medicines to stop cramps	0.164	73.64	26 913
Antibiotics	0.564	253.64	92 701
Total	3.413	1535.15	561 078

Table 3. *Total costs in Maltese liri (Lm) per case*

Resource	Cost per IID case	Total cost per day in Malta	Total cost per year in Malta	% cost of total
Lost productivity	13.43	6044.99	2 209 393	29.75
Health-care seeking	29.54	13290.9	4 558 970	61.38
Medicinal use	3.413	1535.15	561 078	7.55
Stool culture analysis	0.404	181.82	66 452	0.89
Personal costs	0.189	85.32	31 183	0.42
Total costs	46.976	21138.18	7 427 078	

testing of stools and direct personal costs. Indirect costs were the costs involved in missed employment to the case and to caregivers. The total of indirect and direct costs per case are shown in Table 3.

The total direct and indirect costs incurred from IID per case of IID per day amounted to Lm 46.97, which is equivalent to a total cost of LM 21 138 per day or Lm 7 420 708 per year for the whole population.

Costs of IID according to severity

Since the resource units used differed according to the severity of illness, the resource units used by each case were classified according to the degree of severity. Table 4 lists the costs of resource unit used for the three categories of severity of illness. This is equivalent to Lm 6.05 per mild case, Lm 20.48 per moderate case and Lm 168.38 for a severe case.

DISCUSSION

The traditional estimate of disease burden is based on the national surveillance system, which is reliant on

notifications by doctors at GP and hospital level, and by laboratories. This reporting system does not cover those cases in the community who do not seek health-care services so that this study was the first step in estimating the true burden of this condition nationwide at community level. A cross-sectional methodology was chosen for the study in Malta since it is feasible, less costly and less time consuming [17].

The high rate of IID reflects the significant burden of illness at community level. The rate was similar to that estimated for Ireland (4.5%, 95% CI 3.7–5.3), in 2000–2001 [22–24]. IID is usually self-limiting with the majority of cases being of mild and moderate severity so that the majority of the burden is experienced in the community. However, there were some severe cases of illness, often requiring admission to hospital for treatment. Age was related to the degree of severity of illness with children being more likely to have severe illness. This has been seen in other studies and is thought to relate to an under-developed immune system [25, 26].

The number of days taken off from work by cases and by other members of the family to take care of cases was considerable and was related to the severity of illness. The low rate (0.26 days) of missed work per

Table 4. Cost in Maltese liri (Lm) of resources used according to severity of illness of IID in Malta

	Resource used	Mild	Moderate	Severe
Visit to HCP	Emergency	60·00	20·00	100·00
	Doctor	39·00	27·00	18·00
	Health centre	20·00	0·00	0·00
	Hospital	0·00	0·00	2640·00
Personal costs	Other costs	0·98	8·00	9·80
Medicinal use	Painkiller	6·00	7·20	12·00
	Anti-diarrhoeal	33·60	13·44	16·80
	Antihistamine	3·17	0·00	0·00
	Anti-nauseants	9·44	14·16	18·88
	Anti-cramps	4·05	8·10	4·05
	Oral rehydration therapy	57·12	33·60	40·32
	Antibiotics	6·20	12·40	37·20
Stool investigation	Stool culture	20·00	0·00	20·00
Productivity lost	Work lost – self	41·41	280·76	213·69
	Work lost – person accompanying hospitalization	0·00	0·00	624·82
	Work lost – carer	26·03	26·03	117·16
Total		327·00	450·69	3872·72

HCP, Health-care provider.

case of IID in Malta was significantly lower than that found in other international studies. The UK study estimated 3 days for those consulting a GP and 2 days for those who did not [5]. Rates fluctuated in different countries with 4·2 days reported in New Zealand [10, 27]; 1·3 days in Australia [8] and 1·8 days in Canada [16]. The lower number of days of work lost in Malta may be related to the very close family networks resulting in fewer people needing to take time off from work to care for other people in the family. An area of concern is that if symptomatic cases are returning to work in the early phase of illness, this may lead to transmission of illness to other work partners, especially for viral illness where person-to-person transmission usually predominates. The costs of time lost were calculated according to the education level. This assumption may not be correct in all cases since people may work in different jobs than expected by their educational level. This type of error can be reduced by asking for the actual work done and the income for the caregivers and the case, although this may be a sensitive question and responses may not be reliable especially for self-employed persons and those in part-time employment.

Time lost from education was seen to be considerable among those affected and may have had considerable impact especially if it occurred at a crucial

time in the year, for example during examination days. However no value has been placed upon this subjective element here.

GPs are an important contact point for cases of IID. Although there is a well-established public GP service in Malta many patients would prefer to consult their own family doctor. This Maltese study has revealed a higher rate of consultation with GPs than studies in other countries [5, 14]. This is very important for surveillance initiatives since it is clear that almost half of the cases of IID were visiting a GP. Hence GPs can be a target point for surveillance and for encouraging submission of stool samples for analysis. The study in Ireland, with similar rates of IID as in Malta, showed a lower consultation rate of 29·2% [23]. Different health-care systems, accessibility and nationwide health consciousness may affect the consultation rates. Although admission to hospital occurred in a low percentage of cases, the costs of this are very high. Stool sample requests are quite low in Malta when compared to 6·9% in Ireland [23]; 27% in the United Kingdom [28] and 34% in Norway [29]. Similarly, submission rates of samples may be low, hence the high rate of unspecified foodborne illness reported in national statistics via the routine surveillance system may be expected. The findings of this study will help in the interpretation of national surveillance data especially

given consultation rates and stool submission rates for IID.

The use of medicines for the treatment of IID also contributed to a significant cost to the community which is related to the duration and severity of illness. In severe cases, the cost was very high due mainly to hospitalization costs. Cases of IID, use up resources that could be used for other illnesses or other patients. Thus, these costs can reflect the opportunity costs given scarce hospital resources.

This study has shown that IID represents a substantial disease burden in the community with significant costs, of which the health-seeking costs were by far the largest component followed by lost productivity. The cost values reported in this study were substantial, yet they are likely to be an underestimate of the true cost. Some components were not included in the analysis due a to lack of information, e.g. lost leisure time, lost quality of life, lost work which is usually unpaid, psychological factors, lost schooling, chronic sequelae, public health surveillance and investigation and loss to industry. This study did not include the more than one million tourists who visit Malta every year especially in summer so the burden of illness and hence cost to the health service described here is not complete.

It is clear from the findings of this study that interventions to reduce the prevalence of community IID should consider sources of sporadic cases in addition to sources of outbreaks since they add considerably to the burden and costs. These significant additional costs justify efforts to take the necessary measures to control this disease.

ACKNOWLEDGEMENTS

We thank our colleagues working at the Disease Surveillance Unit, within the Department of Public Health for their professionalism and diligence in carrying out the interviews and the respondents for their cooperation. We also thank Dr Malcolm Micallef, Director Public Health; Dr Shannon Majowicz, Epidemiologist at Health Canada and Dr Elaine Scallan, Epidemiologist at CDC Foodborne Diseases Active Surveillance Network (FoodNet) for their invaluable help.

DECLARATION OF INTEREST

None.

REFERENCES

1. **Farthing MJ.** Diarrhoea: a significant worldwide problem. *International Journal of Antimicrobial Agents* 2000; **14**: 65–69.
2. **Guerrant RM, et al.** Magnitude and impact of diarrhoeal diseases. *Archives of Medical Research* 2002; **33**: 351–355.
3. **Kaferstein FK.** Food Safety: a commonly underestimated public health issue. *World Health Statistics Quarterly* 1997; **50**: 3–4.
4. **Mead PS, et al.** Food-related illness and death in the United States. *Emerging Infectious Diseases* 1999; **5**: 607–625.
5. **Roberts JA, et al.** The study of infectious intestinal disease in England: socio-economic impact. *Epidemiology and Infection* 2003; **130**: 1–11.
6. **Buzby JC, Roberts T.** Economic costs and trade impacts of microbial foodborne illness. *World Health Statistics Quarterly* 1997; **50**: 57–66.
7. **Corso PS, et al.** Cost of illness in the 1993 waterborne *Cryptosporidium* outbreak, Milwaukee, Wisconsin. *Emerging Infectious Diseases* 9: 426–431.
8. **Hellard ME, et al.** Cost of community gastroenteritis. *Journal of Gastroenterology and Hepatology* 2003; **18**: 322–328.
9. **Lidqvist R, et al.** A one year study of foodborne illnesses in the Municipality of Uppsala, Sweden. *Emerging Infectious Diseases* 2001; **3** (Suppl.): 588–592.
10. **Scott WG, et al.** Economic cost to New Zealand of foodborne infectious disease. *New Zealand Medical Journal* 2000; **113**: 281–284.
11. **Socket PN, Roberts JA.** The social and economic impact of salmonellosis. *Epidemiology and Infection* 1991; **107**: 335–347.
12. **Todd ECD.** Costs of acute bacterial foodborne disease in Canada and the United States. 1989. *International Journal of Food Microbiology* 1989; **9**: 313–326.
13. **Todd ECD.** Preliminary estimates of costs of foodborne disease in the United States. *Journal of Food Protection* 1989; **52**: 595–601.
14. **Van den Brandhof WEGA, et al.** Costs of gastroenteritis in the Netherlands. *Epidemiology and Infection* 2004; **132**: 211–221.
15. **Mangen MJJ, Havelaar AH, De Wit GA.** Campylobacteriosis and sequelae in the Netherlands –estimating the disease burden and the cost-of-illness. RIVM Report, 250911004/2004.
16. **Majowicz SE, et al.** Burden and cost of gastroenteritis in a Canadian community. *Journal of Food Protection* 2006; **69**: 651–659.
17. **Gauci C, et al.** Challenges in identifying methodology to estimate the prevalence of infectious intestinal disease in Malta. *Epidemiology and Infection* 2006; **134**: 393–399.
18. **Gauci C.** Surveillance of infectious intestinal disease in Malta. Ph.D. Thesis. University of Malta, 2006.
19. **Gauci C, et al.** The magnitude and distribution of infectious intestinal disease in Malta: a population based study. *Epidemiology and Infection* 2007.

- Published online: 15 January 2007. doi: 10.1017/S0950268806007795.
20. **Legal Notice 201 of 2004.** Fees Ordinance (Cap35) Health Care Fees Regulations, Laws of Malta, 2004.
 21. **Health Interview Survey, 2003.** Department of Health Information, Malta.
 22. **Scallan E, et al.** Acute gastroenteritis in Northern Ireland and the Republic of Ireland: a telephone survey. *Communicable Disease and Public Health* 2004; **7**: 61–67.
 23. **Acute Gastroenteritis in Ireland, North and South.** A telephone survey, September 2003 (http://www.fsai.ie/extranet/gastro_report/Acute_Gastroenteritis.pdf). Accessed June 2005.
 24. **Scallan E.** Epidemiology of acute gastroenteritis in the community and management in general practice. October 2003. Ph.D. Thesis. University College, Dublin.
 25. **Monto AS, Koopman JS.** The Tecumseh Study. XI. Occurrence of acute enteric illness in the community. *American Journal of Epidemiology* 1980; **112**: 323–33.
 26. **Herikstad H, et al.** A population based estimate of burden of diarrhoeal illness in the United States: FoodNet 1996–1997. *Epidemiology and Infection* 2002; **129**: 9–17.
 27. **Lake RJ, et al.** Estimated number of cases of fooborne infections in New Zealand. *New Zealand Medical Journal* 200; **113**: 278–281.
 28. **Wheeler JG, et al.** Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to the national surveillance. *British Medical Journal* 1999; **318**: 1046–1050.
 29. **Kuusi M, et al.** Incidence of gastroenteritis in Norway – a population based survey. *Epidemiology and Infection* 2003; **131**: 591–597.